Cooperative Agreement U01CA301988
Award Date
9/26/24
Completion Date
8/31/29
Dollars Obligated
$642K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Cooperative Agreement
Place of Performance
Boston, MA 02114, USA
Similar Awards
The National Cancer Institute (NCI) awarded The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), a Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program. The $140,130 award, which runs from March 1, 2025 to February 28, 2027, will fund research to elucidate the role of thiol reductive stress in lung cancer growth and metastasis. The project aims to investigate how activation of the NRF2 transcriptional regulator disrupts the...
The National Cancer Institute (NCI) awarded a $176,040 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The purpose of this 4/1/2025 - 3/31/2027 grant is to study the effect of aging on CDC1 function and CD8 T cell immunity in tumors. Specifically, the research aims to investigate the mechanisms underlying defective function of aged intratumoral conventional type 1...
This federal Cooperative Agreement award, issued by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, provides $416,745 to the University of Massachusetts Medical School (UMass Medical) to develop an Integrative Analysis and Visualization Platform for Cancer Regulatory Genomics. The project aims to: Create a Regulatory-Element-Target-Gene Atlas that enables researchers to explore connections between regulatory elements and cancer-associated...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $693,781 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research focused on harnessing mutant IDH1 as a therapeutic target in liver cancer and other solid malignancies. The key objectives are to: Further understand how mutant IDH1 causes cancer growth and why resistance arises to IDH1 inhibitor treatments. This will involve...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $662,516 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on improving drug delivery for chemoradiotherapy in locally advanced head and neck squamous cell carcinoma and anaplastic thyroid cancer. The project aims to evaluate how fractionated radiation affects the tumor microenvironment to influence passive drug delivery, and test...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $858,166 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct a randomized trial of a targeted palliative care intervention for patients with metastatic breast cancer. The study aims to improve documentation of end-of-life care preferences, delivery of end-of-life care, and participant-reported outcomes for this patient population....
This Cooperative Agreement awarded by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research) provides $3,942,082 in funding to the President and Fellows of Harvard College (Harvard T.H. Chan School of Public Health) from August 2024 to July 2029. The award supports the Massachusetts Partnership for Community-Engaged Cancer Control Equity (Mass PCECCE) initiative, which aims to advance cancer control equity by strengthening community health centers' capacity to deliver...
This $2,136,715 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) is focused on harnessing DNA methylation in peripheral blood to improve colorectal cancer prevention. The primary awardee, President and Fellows of Harvard College through its Harvard T.H. Chan School of Public Health, will lead the research effort. Key sub-awards have been made to Dana-Farber Cancer Institute and Boston University to contribute...
The General Hospital Corporation (doing business as Massachusetts General Hospital) was awarded a $422,508 Project Grant from the National Cancer Institute (NCI) under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394). The funding will support the development of a new reverse Monte Carlo software for Single Photon Emission Computed Tomography (SPECT) reconstruction. The software will be built from scratch on a GPU platform to speed up simulations, with the goal of...
The federal Project Grant award R01CA297470, totaling $581,723, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research (CFDA 93.395) program. The grant supports the development of a novel hyperspectral single-photon emission microscope system, named Alpha-Scope, for in vivo 3D autoradiography of radiopharmaceuticals and their radioactive daughter radionuclides in small animal studies. This advanced imaging system aims to provide unprecedented resolution and...